StockNasdaqGSALNY
Alnylam Pharmaceuticals
$249.59
+3.49 (+1.42%)today
Valuation & earnings
- P/E ratio
- 43.48
- Forward P/E
- 20.01
- EPS (ttm)
- $5.74
- Forward EPS
- $12.47
- Price/book
- 24.65
- PEG ratio
- 0.32
- Payout ratio
- 0%
Financials (ttm)
- Revenue (ttm)
- 4.8B
- Revenue growth
- 66.9%
- Profit margin
- 16.13%
- Return on equity
- 96.56%
- Total cash
- 3.3B
- Total debt
- 3B
Earnings (EPS)
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Sep 30, 2025 | 1.75 | 2.9 | +66.12% |
| Dec 31, 2025 | 1.5 | 1.25 | -16.5% |
| Mar 31, 2026 | 1.47 | 1.99 | +35.3% |
| Jun 30, 2026 | 2.14 | 1.84 | -14.21% |
Next earnings date: Oct 29, 2026
Analyst view
Consensus ratingBuy29 analysts
Strong buy 6Buy 16Hold 7
12-month price targetsImplied upside: +48.79%
256
371.35
536
LowCurrent priceHigh
Latest news
(English)RNAi drug specialist ADARx raises $446M IPO
BioPharma DiveSep 25, 2026
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
TrefisSep 22, 2026
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
MarketBeatSep 20, 2026
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
MarketBeatSep 20, 2026
Is Alnylam (ALNY) Quietly Repricing Its RNAi Risk Profile Amid Oligonucleotide Market Optimism?
Simply Wall St.Sep 15, 2026
Slate Medicines Names Kenneth Koblan as Chief Scientific Officer
Exec EdgeSep 15, 2026
Related products
How visible is Alnylam Pharmaceuticals in AI search?
We ask AI search engines about Alnylam Pharmaceuticals and its market — live — and measure whether and how prominently the brand appears in their answers.
No AI visibility check has been run for Alnylam Pharmaceuticals yet.
Run a live check to see how AI search engines talk about this brand right now.
Is your brand this visible in AI search?
Aurora tracks your brand across 7 AI search engines — visibility, share of voice and the sources that shape AI answers.